CF
AVBP icon

Corebridge Financial’s ArriVent BioPharma AVBP Stock Holding History

Corebridge Financial’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,803
Closed -$255K – 2885
2025
Q1 		$255K Sell
13,803
-204
-1% -$4.99K ﹤0.01% 1923
2024
Q4 		$373K Sell
14,007
-1,057
-7% -$30.3K ﹤0.01% 1829
2024
Q3 		$354K Buy
15,064
+9,783
+185% +$222K ﹤0.01% 1910
2024
Q2 		$98K Buy
+5,281
New +$94.2K ﹤0.01% 2613

Other funds holding AVBP

HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
GCGM
General Catalyst Group Management Cambridge, Massachusetts $184M AUM 50.45% 1-Year Est. Return

Corebridge Financial's AVBP Position: Q2 2025 in Review

Corebridge Financial sold out of ArriVent BioPharma (AVBP) in Q2 2025, closing a stake of 13,803 shares — an estimated $255K sold.

Corebridge Financial first reported a position in AVBP in Q2 2024 and held it in 4 quarters. The position peaked at $373K in Q4 2024. 99 funds tracked by Wall St. Rank hold AVBP as of Q2 2025.

  • Corebridge Financial reported no remaining ArriVent BioPharma position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 13,803 ArriVent BioPharma shares in Q2 2025, an estimated $255K.
  • Corebridge Financial first reported a position in ArriVent BioPharma in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's ArriVent BioPharma position peaked at $373K in Q4 2024.
  • 99 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.